Haleon PLC Executes Share Buyback to Strengthen Market Position

Haleon PLC ( (GB:HLN) ) has issued an update.

Haleon PLC has announced the purchase of 825,666 ordinary shares for cancellation as part of its share buyback program initiated in March 2025. This transaction reflects the company’s strategic move to optimize its capital structure, potentially enhancing shareholder value and maintaining a robust market position. The updated share capital now stands at 9,012,587,392 ordinary shares, with 9,008,507,187 shares possessing voting rights.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score of 76 reflects its solid financial performance, strategic growth initiatives, and positive market sentiment. The company’s effective cash flow management and strategic focus on innovation and market expansion are significant strengths. However, caution is warranted due to valuation concerns and external challenges, such as currency fluctuations.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across six major categories, including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon’s well-known brands, such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, are recognized for their trusted science, innovation, and deep human understanding.

Average Trading Volume: 28,348,713

Technical Sentiment Signal: Buy

Current Market Cap: £36.4B

For an in-depth examination of HLN stock, go to TipRanks’ Stock Analysis page.